Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the
HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the …

Background. Women in Africa, especially young women, have very high human immunodeficiency
virus (HIV) incidence rates that cannot be fully explained by behavioral risks. We …

Rare Thromboembolic Events among Vaccinated South Africans Among 288,368 South
African health care workers who received the Ad26.COV2.S vaccine, no cases of vaccine-…

Background The effect of the COVID-19 pandemic on HIV outcomes in low-income and
middle-income countries is poorly described. We aimed to measure the impact of the 2020 …

Background More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide
in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been …

Using an expression cloning strategy that relies on a functional assay, we have cloned a
novel Xenopus homeobox-containing gene, Siamois. Embryos injected in a ventral-vegetal …

Vaccine Effectiveness against Omicron in South Africa South Africa has a population with a
high baseline level of Covid-19. During the recent surge in the omicron variant, the …

Background A safe, effective vaccine is essential to eradicating human immunodeficiency
virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/…

The early widespread dissemination of Omicron indicates the urgent need to better
understand the transmission dynamics of this variant, including asymptomatic spread among …

The epitopes defined by HIV-1 broadly neutralizing antibodies (bNAbs) are valuable templates
for vaccine design, and studies of the immunological development of these antibodies …